Cell and gene therapy manufacturing 1200x628

Why cell and gene therapy manufacturing is expanding in Europe

November 09, 2026

 

Cell and gene therapies are creating new manufacturing requirements for pharmaceutical companies. European R&D and production sites need scientific expertise, specialised infrastructure and reliable processes.

Lithuania is adding advanced-therapy capacity to its established biotechnology base. Northway Biotech’s new Vilnius facility shows how this translates into infrastructure for international developers and manufacturers.

What is driving cell and gene therapy manufacturing in Europe?

Clinical use is growing. The European Society for Blood and Marrow Transplantation (EBMT) 2024 survey, published in 2026, recorded 6,082 CAR-T patients across its reporting network, up 24.5% from 2023.

The pipeline is expanding too. ASGCT-Citeline’s Q3 2026 report counted 62 Phase III gene therapy programmes globally, including genetically modified cell therapies, compared with 47 a year earlier.

For manufacturers, these trends make reliable clinical and commercial supply a priority. Patient-specific batches, traceability and contamination control require specialised processes, not just more factory space.

Specialised CDMOs and in-house manufacturing

A cell therapy CDMO is a contract development and manufacturing organisation providing development and production services for cell-based therapies.

A specialist CDMO offers process expertise and Good Manufacturing Practice (GMP) infrastructure without requiring a developer to build its own facility. Companies establishing in-house operations need the same capabilities, alongside suitable sites and talent.

DNA

Lithuania’s cell and gene therapy manufacturing capabilities

In September 2026, Northway Biotech opened a €61 million, 3,500 sq. m cell therapy and personalised medicine centre in Vilnius.

According to Northway, it is designed for up to 20 independent cGMP manufacturing lines, supporting autologous and allogeneic cell therapies, personalised therapeutic vaccines and regenerative medicine applications.

Its segregated processing areas and quality-control laboratories support parallel workflows while maintaining product identity and contamination control. For developers, this provides access to specialised cell-processing capacity and an experienced team, subject to technology transfer and process compatibility.

Northway’s local platform also includes biologics manufacturing and an operating gene therapy centre. BIO CITY is being developed in stages: the developer’s proposed investment of up to €7 billion covers the wider, long-term campus plan.

Lithuania’s biotech ecosystem: scale, research and talent

Lithuania has more than 300 life sciences companies. An August 2026 government update put the wider life sciences, biotechnology and health-technology sector at around 3.7% of national GDP.

Thermo Fisher Scientific combines life-science manufacturing and R&D in Vilnius, while Teva Baltics develops and produces recombinant biopharmaceuticals. Both demonstrate an established local base for complex biotechnology operations.

Caszyme and Atrandi Biosciences add complementary research capabilities: CRISPR gene-editing tools and single-cell analysis technology, respectively.

Vilnius University’s Life Sciences Center also partners with EMBL on genome editing, scientific services and training, connecting the ecosystem to international research.

Assessing Lithuania for a European manufacturing investment

For companies considering European operations, Lithuania brings together biomanufacturing experience, genome-editing research and specialist technology developers. These capabilities are relevant to R&D, process development and production projects.

A site assessment should test GMP expertise, technology-transfer readiness, talent, utilities, cold-chain logistics and room to expand. Costs and technical suitability depend on the therapy and production model.

Invest Lithuania provides free support with site selection, local introductions, establishment and expansion. Its team helps investors assess talent and infrastructure and navigate setup requirements.

Considering a biotechnology R&D or manufacturing investment in Europe? Contact Invest Lithuania to discuss your project.

FAQs
Link to page

What makes Lithuania’s Biotech industry stand out?

Explore a fast-growing biotechnology ecosystem powered by robust R&D, strong governmental support, and a skilled workforce.

Subscribe CTA image

Enjoy reading our news?

Please wait...

Thank you for subscribing to our newsletter!

Contact us

Want to learn more about the latest updates?

Invest Lithuania is here to keep you informed about the latest news, opportunities, and developments shaping Lithuania’s business landscape. If you have any questions or would like more details, feel free to contact us—we’re here to provide the insights you need.